MARKET

AEZS

AEZS

Aeterna Zentaris
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3300
-0.0250
-7.04%
After Hours: 0.3300 0 0.00% 16:30 01/27 EST
OPEN
0.3500
PREV CLOSE
0.3550
HIGH
0.3599
LOW
0.3111
VOLUME
1.25M
TURNOVER
--
52 WEEK HIGH
3.620
52 WEEK LOW
0.2941
MARKET CAP
40.03M
P/E (TTM)
-4.9401
1D
5D
1M
3M
1Y
5Y
BRIEF-Aeterna Zentaris Granted 180-Day Extension By Nasdaq To Regain Compliance With Minimum Bid Price Rule
reuters.com · 23h ago
Aeterna Zentaris Granted 180-Day Extension By Nasdaq To Regain Compliance With Minimum Bid Price Rule
Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and
Benzinga · 23h ago
Aeterna Zentaris gets 180-day extension to comply with Nasdaq's minimum bid price rule
Aeterna Zentaris (NASDAQ:AEZS) receives a notice from Nasdaq, which grants an additional 180 calendar days, through Jul. 23, to evidence compliance with the $1 minimum bid price requirement for continued
Seekingalpha · 1d ago
Aeterna Zentaris provides pipeline updates
Aeterna Zentaris (NASDAQ:AEZS) provided pipeline update and business outlook. Aeterna CEO Klaus Paulini said that in 2021 the company in-licensed six new pre-clinical development programs, four therapeutics and two vaccines,
Seekingalpha · 1d ago
BRIEF-Aeterna Zentaris Provides Business Outlook
reuters.com · 1d ago
Aeterna Zentaris Provides Business Outlook And Outlines Pipeline Priorities
– Company advancing diversified portfolio focused on areas of significant unmet medical need – Supported by solid financial position with cash to fund operations beyond 2023 TORONTO, ONTARIO, Jan. 26, 2022
Benzinga · 1d ago
Aeterna Zentaris to Present at the Virtual Investor 2022 Top Picks Conference
– Live video webcast presentation on Wednesday, January 26th at 9:00 AM ET CHARLESTON, S.C., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing a...
GlobeNewswire · 01/20 13:05
JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th
\- Access the event and schedule of presenting companies at virtualinvestorco.com -\- Live video webcast presentations of participating companies followed by interactive Q&A session -PITTSTOWN, NJ / ACCESSWIRE / January 12, 2022 /JTC Team ("JTC"), a fully ...
ACCESSWIRE · 01/12 15:35
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AEZS. Analyze the recent business situations of Aeterna Zentaris through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average AEZS stock price target is 2.000 with a high estimate of 2.000 and a low estimate of 2.000.
High2.000
Average2.000
Low2.000
Current 0.3300
EPS
Actual
Estimate
-0.02-0.01-0.01-0.00
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 45
Institutional Holdings: 2.16M
% Owned: 1.78%
Shares Outstanding: 121.30M
TypeInstitutionsShares
Increased
8
476.64K
New
3
10.98K
Decreased
10
281.59K
Sold Out
5
255.99K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.90%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
Non-Executive Chairman/Independent Director
Carolyn Egbert
President/Chief Executive Officer/Director
Klaus Paulini
Chief Financial Officer/Senior Vice President
Giuliano La Fratta
Senior Vice President/Managing Director
Eckhard Gunther
Senior Vice President
Nicola Ammer
Vice President - Finance
Guenther Grau
Vice President
Matthias Gerlach
Director
Dennis Turpin
Independent Director
Pierre-Yves Desbiens
Independent Director
Peter Edwards
Independent Director
Gilles Gagnon
No Data
  • All
  • Financials
  • Insiders
More
About AEZS
Aeterna Zentaris Inc. is a specialty biopharmaceutical company. The Company is focused on developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. Its business is to finalize the development, manufacturing, registration and commercialization of Macrilen (macimorelin). Macrilen (macimorelin) is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor (GHSR-1a) and that has potential uses in both endocrinology and oncology indications. Macimorelin is the oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is leveraging the clinical and compelling safety profile of macimorelin in developing diagnosis of childhood-onset growth hormone deficiency (CGHD) in collaboration with Novo Nordisk.

Webull offers kinds of AEterna Zentaris Inc. (USA) stock information, including NASDAQ:AEZS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AEZS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AEZS stock methods without spending real money on the virtual paper trading platform.